ArticleOncology research2025

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.

Dexue Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.